Table 4.
Leptin and ghrelin concentrations at baseline and at end of follow-up by response to treatment in patients with hepatitis C virus genotypes-1 and -3, as well as mixed effect model derived estimates of the differences in mean scores (mean ± SD)
| Variable | Baseline | End of follow-up | P-value for the adjusted difference1 |
| Genotype 1 SVRs | |||
| Leptin (ng/mL) | 37.66 (10.39) | 26.69 (11.77) | 0.001 |
| Ghrelin (ng/mL) | 0.286 (0.167) | 0.456 (0.254) | 0.001 |
| Genotype 1 non-SVRs | |||
| Leptin (ng/mL) | 49.67 (13.44) | 43.58 (16.17) | 0.060 |
| Ghrelin (ng/mL) | 0.190 (0.119) | 0.239 (0.213) | 0.320 |
| Genotype 3 SVRs | |||
| Leptin (ng/mL) | 24.33 (7.98) | 23.27 (9.54) | 0.510 |
| Ghrelin (ng/mL) | 0.778 (0.654) | 0.420 (0.321) | 0.001 |
| Genotype 3 non-SVRs | |||
| Leptin (ng/mL) | 28.20 (9.72) | 26.70 (6.82) | 0.610 |
| Ghrelin (ng/mL) | 0.564 (0.324) | 0.450 (0.261) | 0.470 |
1
Adjusted for both leptin and ghrelin concentrations.